Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy is organized by i3 Health.
Dates Available:
August 13, 2025 - August 12, 2026
Statement of Need:
Hereditary amyloid transthyretin (ATTR) amyloidosis is a progressively debilitating disease caused by the buildup of variant transthyretin proteins in amyloid deposits in the heart, nerves, and digestive system. Symptoms of ATTR amyloidosis with cardiomyopathy (ATTR-CM) overlap with those of other more commonly recognized cardiac diseases, leading to misdiagnosis. As ATTR is now a treatable disease due to recent advances, it is crucial for members of the interdisciplinary care team to remain up to date on genetic testing and diagnostic modalities to improve early identification for early diagnosis and optimal treatment selection (American Heart Association, 2024; Nativi-Nicolau et al, 2021). This activity, presented by Mathew Maurer, MD, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will explore strategies for increasing detection and improving outcomes in patients with hereditary ATTR-CM.
Learning Objectives:
Upon completion of this activity, participants should be able to:
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
Mathew Maurer, MD, discloses that he has served on an advisory board or panel for Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer; and that he has received grants/research support from Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer.
The i3 Health planners, reviewers, and managers have nothing to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT
This activity is supported by an independent medical education grant from Alnylam U.S., Inc.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.
The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.